AstraZeneca Aims to Transform Cancer Treatment and Advance Clinical Practice with Data Presented at ESMO 2020

Pivotal overall survival data confirm benefit of Lynparza use in advanced prostate cancer Data in early treatment of lung cancer highlight potential to improve patient outcomes in curative-intent settings with Tagrisso and Imfinzi San Francisco, CA (UroToday.com) — AstraZeneca will present new developments in pursuit of its ambition to eliminate cancer as a cause of death at […]

Research at ESMO Virtual Congress 2020 Highlights Significant Progress in Cancers with High Unmet Medical Need

Late-breaking data from pivotal Phase 3 CheckMate -577 and CheckMate -649 trials to be featured in ESMO Presidential Symposium III and highlight potential for Opdivo (nivolumab) and Opdivo-based regimens to change standard of care in early and advanced stages of certain esophageal and gastric cancers Detailed results from CheckMate -9ER, presented in partnership with Exelixis, Inc. and featured […]

Bayer to Present New Data from Evolving Oncology Portfolio at ESMO 2020

Long-term efficacy and safety results of an integrated data set for Vitrakvi® (larotrectinib), as well as sub-analyses, to be presented in poster sessions Tolerability and treatment response data from the Phase III ARAMIS trial investigating NUBEQA® (darolutamide) in men with non-metastatic castration-resistant prostate cancer (nmCRPC) Continued research to explore potential of marketed products, evaluating the investigational use […]

X